Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Post by jomagon Jul 09, 2021 1:47pm
238 Views
Post# 33521932

News from last night

News from last night

 

iCo receives TSX-V conditional OK for Satellos deal

 

2021-07-08 20:19 ET - News Release

 

Mr. William Jarosz reports

ICO THERAPEUTICS INC. ANNOUNCES TSX VENTURE EXCHANGE CONDITIONAL APPROVAL AND PROVIDES UPDATE REGARDING BUSINESS COMBINATION WITH SATELLOS BIOSCIENCE INC.

iCo Therapeutics Inc. has received formal conditional approval from the TSX Venture Exchange of iCo's proposed business combination with Satellos Bioscience Inc.

The company has filed an information circular on SEDAR that describes the transaction in detail and will be mailing the circular to shareholders on or about July 13, 2021. iCo has set Aug. 3, 2021, as the date of the special meeting of shareholders of the company to approve the transaction, in accordance with the rules of the exchange. The shareholder meeting is more fully described in the circular.

In connection with the transaction, iCo previously announced, on April 27, 2021, the successful closing of a private placement of 85,294,117 subscription receipts at a price of 8.5 cents per subscription receipt for aggregate gross proceeds of approximately $7.25-million, conditional upon successful closing of the transaction. The subscription receipts will convert into common shares of iCo following the satisfaction of the escrow release conditions attached to the subscription receipts.

Finally, iCo announces that if the transaction is approved by iCo and Satellos shareholders, the company expects trading of the shares of the combined company to begin trading on the exchange as Satellos Bioscience Inc. under the symbol MSCL during the week of Aug. 9, 2021.

William Jarosz, the chief executive officer of iCo, noted: "We are grateful to the exchange for their diligent work in approving this transaction. We are also grateful for the continuing support of iCo's shareholders, both in participating in the financing and for their patience during this time of change for the company. We have a number of new strategic initiatives underway that involve the new assets and technology platform from Satellos and our older legacy assets. We believe we are beginning a new era for iCo and its shareholders."

About iCo Therapeutics Inc.

iCo is a Canadian biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat ocular and infectious diseases.

iCo generally focuses on in-licensing drug candidates with a clinical history and redose, reformulate, and develop drug candidates for the treatment of ocular and infectious diseases. iCo assumes the clinical, regulatory and commercial development activities for its product candidates and advances such candidates along the regulatory and clinical pathway toward commercial approval. iCo believes its approach may reduce the risk, time and cost of developing therapeutics by avoiding some of the uncertainty associated with certain research and preclinical stages of drug development.

iCo currently has two in-licensed product candidates in various stages of development: iCo-008 (or for potential use in eotaxin-1 mediated indications, sublicensed to Alexion Pharmaceuticals Inc., and an oral Amphotericin B delivery system under internal development for potential use in fungal infections).

We seek Safe Harbor.

<< Previous
Bullboard Posts
Next >>